Work

Angiogenesis inhibition in metastatic hormone refractory prostate cancer (HRPC): A randomized phase II trial of two doses of the matrix metalloproteinase inhibitor (MMPI) BMS-275291

Year: 2004

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2004.22.14_suppl.4647

Authors: P. N. Lara, J. Longmate, W. Stadler, D. I. Quinn, P. Twardowski, C. I. Martel, N. J. Vogelzang, E. E. Vokes, J. H. Doroshow, D. R. Gandara

Institutions: University of Southern California, City Of Hope National Medical Center, City of Hope, UC Davis Comprehensive Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2242563296

Cites:

Cited by: 8

Related to: 10